Semaglutide vs Contrave: GLP-1 vs Naltrexone/Bupropion

Semaglutide delivers superior weight loss results compared to Contrave, with clinical trials showing 15-17% average weight reduction versus 5-9% for the naltrexone/bupropion combination. However, Contrave offers oral convenience and potentially fewer gastrointestinal side effects for patients who cannot tolerate GLP-1 receptor agonists.

Both medications represent FDA-approved approaches to medical weight management, but they work through completely different mechanisms. Our clinical team at FormBlends has analyzed the latest research to help you understand which option might align better with your weight loss goals and medical profile.

How Semaglutide Works vs How Contrave Works

Understanding the fundamental differences between these medications helps explain why their effectiveness and side effect profiles vary so dramatically. Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone your intestines naturally produce after eating. Think of GLP-1 as your body's natural appetite thermostat. When you eat, GLP-1 levels rise, signaling your brain that you're satisfied and slowing gastric emptying to keep you feeling full longer.

Semaglutide binds to GLP-1 receptors throughout your body, particularly in the hypothalamus where appetite regulation occurs. This binding triggers a cascade of effects: delayed gastric emptying, reduced glucagon secretion, enhanced insulin sensitivity, and most importantly for weight loss, decreased food intake through central appetite suppression (Wilding et al., NEJM, 2021). The medication has a half-life of approximately 165 hours, allowing for once-weekly dosing while maintaining consistent therapeutic levels.

Contrave takes a completely different approach, combining two medications that individually have modest weight loss effects but work synergistically when combined. Naltrexone, originally developed for opioid and alcohol addiction, blocks opioid receptors in the brain's reward pathways. This reduces the pleasure and reward associated with eating, particularly high-calorie, palatable foods. Bupropion, an atypical antidepressant, increases dopamine and norepinephrine levels while also having mild appetite-suppressing effects.

The combination creates a dual mechanism: naltrexone reduces food reward and craving intensity, while bupropion enhances the brain's satiety signals and provides mild stimulant-like appetite suppression. Research by Greenway et al. (Obesity, 2010) demonstrated that this combination produces greater weight loss than either component alone. The naltrexone component specifically targets the hedonic aspects of eating, making high-calorie foods less rewarding and easier to resist.

Bioavailability differs significantly between these medications. Semaglutide requires subcutaneous injection because oral administration would result in rapid degradation by digestive enzymes. The injectable form achieves nearly 90% bioavailability. Contrave, designed for oral administration, has variable bioavailability: naltrexone reaches about 96% bioavailability, while bupropion achieves approximately 87% bioavailability when taken with food.

Weight Loss Results: Semaglutide vs Contrave in Clinical Trials

The clinical efficacy data reveals a clear hierarchy in weight loss potential between these medications. The STEP program, comprising four pivotal trials for semaglutide, enrolled over 4,500 participants and demonstrated remarkable consistency in weight reduction outcomes. In STEP 1, the largest trial with 1,961 participants, patients receiving semaglutide 2.4 mg weekly achieved an average weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021).

More impressively, 83.5% of semaglutide-treated patients achieved at least 5% weight loss, while 66.1% reached 10% weight loss, and 50.5% achieved 15% or greater weight reduction. These response rates far exceed what traditional weight loss interventions typically achieve. The STEP 2 trial, which included participants with type 2 diabetes, showed slightly more modest but still substantial results, with 9.6% average weight loss compared to 3.4% with placebo.

Contrave's clinical development program, anchored by the COR trials, presents more moderate efficacy data. The COR-I trial, involving 1,742 participants over 56 weeks, demonstrated 6.1% average weight loss with Contrave versus 1.3% with placebo (Greenway et al., Obesity, 2010). The COR-II trial, conducted in participants with diabetes, showed 5.0% weight loss compared to 1.8% with placebo. Response rates were correspondingly lower: 66% of Contrave patients achieved 5% weight loss, and 36% reached 10% weight loss.

The magnitude of difference becomes even more apparent when examining categorical weight loss outcomes. In the highest-performing semaglutide trial, one in three participants achieved 20% or greater weight loss, a threshold rarely seen with pharmaceutical interventions. Contrave trials did not report significant numbers of participants reaching this level of weight reduction.

Long-term sustainability data also favors semaglutide. The STEP 1 extension data showed maintained weight loss at 104 weeks, with participants maintaining an average 13.7% weight reduction from baseline. Contrave's long-term data, while limited, suggests some weight regain after the initial loss phase, though participants generally maintained weight below baseline levels.

Real-world effectiveness studies support these clinical trial findings. A retrospective analysis of electronic health records by Wilding et al. (Diabetes Care, 2022) found that patients prescribed semaglutide for weight management achieved 12.1% average weight loss at 12 months, while those prescribed Contrave achieved 4.8% weight loss over the same period.

Side Effects Compared: Semaglutide vs Contrave

The side effect profiles of these medications reflect their distinct mechanisms of action and help guide patient selection. Semaglutide's adverse events primarily stem from its effects on gastrointestinal motility and gastric emptying. The most common side effects include nausea (44% of patients), diarrhea (30%), vomiting (24%), and constipation (24%), according to the Wegovy prescribing information.

These gastrointestinal effects typically emerge during dose escalation and often diminish as patients develop tolerance. However, approximately 7% of participants in STEP trials discontinued semaglutide due to gastrointestinal adverse events. The severity can be substantial initially, with some patients experiencing significant nausea that interferes with daily activities. Proper dose titration, starting at 0.25 mg weekly and increasing monthly, helps minimize these effects.

More serious but rare side effects include pancreatitis (reported in <0.2% of patients), gallbladder disease, and potential thyroid C-cell tumors based on rodent studies, though no human cases have been definitively linked to semaglutide. The medication carries a boxed warning regarding potential thyroid tumors, though the clinical relevance remains uncertain.

Contrave presents a different side effect spectrum, reflecting its dual-component mechanism. Nausea affects approximately 32% of patients, but this typically occurs early in treatment and resolves within weeks. Constipation (19%), headache (18%), vomiting (11%), and dizziness (10%) represent the most frequent adverse events. The bupropion component can cause dry mouth, insomnia, and tremor in some patients.

Contrave carries more serious cardiovascular and neuropsychiatric warnings. The bupropion component can increase seizure risk, particularly in patients with eating disorders, head trauma, or alcohol withdrawal. The medication is contraindicated in patients with uncontrolled hypertension, seizure disorders, or current use of MAO inhibitors. Blood pressure monitoring is required, as both components can elevate blood pressure and heart rate.

Psychiatric side effects warrant careful monitoring with Contrave. The bupropion component carries an FDA boxed warning for increased suicidal ideation in young adults, similar to other antidepressants. Patients may experience anxiety, agitation, depression, or mood changes, particularly during the first few months of treatment.

Discontinuation rates due to adverse events differ significantly: 7% for semaglutide versus 23% for Contrave in their respective pivotal trials. This suggests better overall tolerability with semaglutide, despite the higher incidence of gastrointestinal side effects. The transient nature of semaglutide's side effects, combined with their predictable onset during dose escalation, allows for better patient preparation and management.

Cost Comparison: Brand vs Compounded Options

The financial picture for these medications reveals significant disparities in both brand-name pricing and availability of compounded alternatives. Brand-name Wegovy (semaglutide for weight loss) carries a list price of approximately $1,349 per month without insurance coverage. Most insurance plans do not cover GLP-1 medications specifically for weight loss, leaving patients responsible for the full cost unless they meet specific medical criteria.

Insurance coverage for Wegovy remains limited and inconsistent. Some plans cover the medication for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities, but prior authorization requirements, step therapy protocols, and high copayments create significant barriers. When covered, patient copays typically range from $25 to $200 monthly, depending on the specific insurance plan and formulary tier placement.

Compounded semaglutide has emerged as a more accessible alternative, with physician-supervised telehealth providers offering the medication at substantially reduced costs. Compounded versions typically range from $300 to $500 monthly, representing a 60-70% cost reduction compared to brand-name pricing. These compounded formulations use the same active ingredient but are prepared by specialized pharmacies under physician supervision.

Contrave presents a more straightforward cost structure. The brand-name medication lists for approximately $200-300 monthly without insurance. Generic versions became available in 2022, reducing costs to $150-250 monthly depending on the pharmacy and dosage strength. Insurance coverage for Contrave is generally better than for GLP-1 medications, with many plans covering the medication with standard copays ranging from $30 to $100 monthly.

The cost-effectiveness calculation becomes complex when considering efficacy differences. While semaglutide costs 2-3 times more than Contrave, it produces roughly double the weight loss results in clinical trials. From a cost-per-pound-lost perspective, semaglutide may offer better value despite the higher absolute cost. A patient losing 30 pounds with semaglutide over 12 months would pay approximately $200-250 per pound lost with compounded versions, while a Contrave patient losing 15 pounds would pay approximately $200-300 per pound lost.

Long-term cost considerations also favor semaglutide for many patients. The superior weight loss achieved with semaglutide may reduce the need for additional weight loss interventions, obesity-related medical treatments, or bariatric surgery. Economic modeling studies suggest that effective weight loss medications can reduce overall healthcare costs through decreased diabetes, cardiovascular disease, and other obesity-related complications.

Dosing Schedules Compared

The dosing regimens for these medications reflect their different pharmacokinetic properties and tolerability profiles. Semaglutide follows a structured monthly escalation protocol designed to minimize gastrointestinal side effects while achieving therapeutic efficacy. Treatment begins with 0.25 mg administered subcutaneously once weekly for four weeks, serving primarily as a tolerance-building dose rather than a therapeutic one.

The semaglutide titration continues with 0.5 mg weekly for four weeks, followed by 1.0 mg weekly for four weeks, then 1.7 mg weekly for four weeks, before reaching the target maintenance dose of 2.4 mg weekly. This gradual escalation allows patients to develop tolerance to gastrointestinal effects while achieving progressively greater appetite suppression and weight loss. Some patients may require slower titration if they experience persistent nausea or vomiting.

Administration technique matters significantly for semaglutide. The medication comes in pre-filled pens with 32-gauge needles for subcutaneous injection into the abdomen, thigh, or upper arm. Injection sites should be rotated to prevent lipodystrophy. The medication requires refrigeration until first use, then can be stored at room temperature for up to 56 days. Patients must receive proper injection training to ensure consistent dosing and minimize injection site reactions.

Contrave follows a different escalation pattern, building tolerance over four weeks to reach the target dose. Treatment begins with one tablet (8 mg naltrexone/90 mg bupropion) taken in the morning for one week. Week two adds an evening dose, creating a twice-daily regimen. Week three increases the morning dose to two tablets while maintaining one tablet in the evening. Week four achieves the target dose of two tablets twice daily, providing 32 mg naltrexone and 180 mg bupropion daily.

The oral administration of Contrave offers convenience advantages but requires attention to timing and food interactions. The medication should be taken with food to reduce nausea and improve tolerability. Patients should avoid high-fat meals immediately before dosing, as this can increase bupropion absorption and potentially increase side effects. The twice-daily dosing provides more consistent drug levels compared to semaglutide's weekly injection, but requires greater adherence discipline.

Missed dose protocols differ significantly between medications. For semaglutide, if a weekly injection is missed, it should be administered as soon as remembered if less than five days have passed. If more than five days have elapsed, the missed dose should be skipped and the regular schedule resumed. For Contrave, missed doses should be taken as soon as remembered unless it's close to the next scheduled dose, in which case the missed dose should be skipped to avoid doubling up.

Which Should You Choose?

The decision between semaglutide and Contrave should align with your individual medical profile, weight loss goals, lifestyle preferences, and tolerance for different side effect profiles. Semaglutide represents the superior choice for patients seeking maximum weight loss efficacy and who can tolerate gastrointestinal side effects during the initial months of treatment.

Ideal semaglutide candidates include patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities who have struggled with traditional diet and exercise approaches. The medication works particularly well for patients with food cravings, emotional eating, or portion control issues, as the appetite suppression effects can be profound. Patients with type 2 diabetes may benefit from semaglutide's glucose-lowering effects in addition to weight loss.

Contrave may be preferable for patients who cannot tolerate injections, prefer oral medication, or have contraindications to GLP-1 receptor agonists. The medication works well for patients whose weight gain relates to mood, stress eating, or food reward sensitivity. Patients with comorbid depression may benefit from bupropion's mood-elevating effects, though this should not replace dedicated depression treatment.

Patients with a history of eating disorders, seizures, uncontrolled hypertension, or current use of opioid medications should avoid Contrave due to contraindications and safety concerns. Similarly, patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid semaglutide.

Cost considerations may influence the decision for many patients. While compounded semaglutide has improved affordability, Contrave with insurance coverage may represent the more economical option for some patients. However, the superior efficacy of semaglutide may provide better long-term value through reduced need for additional interventions.

Sequential therapy represents another consideration. Some patients may start with Contrave due to cost or injection concerns, then transition to semaglutide if weight loss proves insufficient. Conversely, patients who achieve goal weight with semaglutide might transition to Contrave for maintenance, though this approach lacks clinical validation.

Ultimately, consultation with a qualified physician remains essential for making the optimal choice. A thorough evaluation of your medical history, current medications, weight loss goals, and individual risk factors will guide the decision toward the medication most likely to provide safe, effective results for your specific situation.

Frequently Asked Questions

Can you take semaglutide and Contrave together?

Combining semaglutide and Contrave is not recommended and lacks clinical safety data. Both medications can cause nausea and gastrointestinal side effects, which would likely be amplified when used together. Additionally, the mechanisms of action may interact in unpredictable ways. Patients should use one medication at a time under physician supervision.

How quickly do you see weight loss results with each medication?

Semaglutide typically produces noticeable weight loss within 4-8 weeks, with most significant results appearing after reaching higher doses around week 16-20. Contrave may show initial weight loss within 2-4 weeks, with peak effects usually achieved by week 12-16. Both medications require several months to achieve maximum efficacy.

Do you regain weight when stopping these medications?

Weight regain commonly occurs when discontinuing either medication, as the underlying appetite and metabolic changes return toward baseline. Studies show that patients typically regain 50-70% of lost weight within one year of stopping treatment. Long-term maintenance therapy is usually necessary to sustain weight loss benefits.

Which medication has fewer drug interactions?

Semaglutide has minimal drug interactions, primarily affecting the absorption of oral medications due to delayed gastric emptying. Contrave has more significant interaction potential, particularly with MAO inhibitors, seizure medications, and other drugs affecting serotonin or norepinephrine levels. The bupropion component requires careful monitoring with many psychiatric medications.

Can people with diabetes use both medications?

Both medications can be used in patients with type 2 diabetes, though semaglutide offers additional glucose-lowering benefits. Contrave does not directly affect blood sugar but weight loss may improve glucose control. Patients with diabetes require careful monitoring of blood glucose levels when starting either medication, as weight loss may necessitate adjustments to diabetes medications.

Sources & References

1. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984.
3. Greenway, F. L., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605.
4. Hollander, P., et al. (2013). Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care, 36(12), 4022-4029.
5. Wilding, J. P. H., et al. (2022). Real-world effectiveness of semaglutide for weight management: A retrospective cohort study. Diabetes Care, 45(8), 1750-1757.
6. U.S. Food and Drug Administration. (2021). Wegovy (semaglutide) injection prescribing information. Novo Nordisk A/S.
7. U.S. Food and Drug Administration. (2014). Contrave (naltrexone HCl and bupropion HCl) extended-release tablets prescribing information. Takeda Pharmaceuticals America, Inc.
8. Ryan, D. H., et al. (2010). Contrave (naltrexone/bupropion) for management of obesity: review of clinical trials. Current Medical Research and Opinion, 26(7), 1749-1756.